At ACR23 I had a twitter-disagreement about steroid tapers from PEXIVAS with Mike Walsh, the lead author on the PEXIVAS trial. He kindly agreed to join me for a moderated discussion. Loved hearing his perspective and have to admit he pulled me closer to his practice... but not all the way there. Longer podcast than usual but I prefer to release aud…

Rheum4Debate is back! In this episode I moderated a debate between two pulmonologists about RA-ILD. As a reminder, Rheum4Debate is an Oxford-style debate show, where two debators disagree over a motion during 3 rounds of discussion. The motion for todays show was: “Asymptomatic patients with rheumatoid arthritis and high risk features for interstit…

Nice study this week on an important topic. Can we prevent the development of rheumatoid arthritis by initiating DMARDs during a preclinical phase? Lots to discuss: what does it mean to be "pre-clinical?" How does this fit with other studies of this nature? Check it out! https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02650-8/ful…

Informative podcast this week with Dr. Alexander Oldroyd, the first author of the recently published "International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening." The article itself appeared in Nature Reviews Rheumatology and provides what I think is a very useful framework for approaching this issue. Article: https://…

Quick methodology episode this week discussing the concept of "fragility" in randomized controlled trials of lupus. Really enjoyed discussing this paper and was grateful to have been a part of it. Get the text here: https://lupus.bmj.com/content/lupusscimed/11/1/e001068.full.pdfBy Michael Putman

Today I'm taking another twitter discussion into the podcast realm! Dr. Bhaskar Dasgupta has published hundreds of papers about polymyalgia rheumatica and giant cell arteritis, including a recent publication in Nature Reviews: Rheumatology that piqued my interest (https://www.nature.com/articles/s41584-023-00976-8). In this podcast we discuss scree…

Interesting topic and interesting paper this year, including discussion of observational biases, positive and negative controls, and interpreting data as it comes. Paper: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2810259By Michael Putman

In this podcast, clinical experts discuss key findings presented during the past year on current and emerging therapies for managing uncontrolled gout.

In this podcast, clinical experts discuss key findings presented during the past year on evidence-based tools for detection and assessment of uncontrolled gout.

In this podcast, clinical experts discuss key findings presented during the past year on disease burden and comorbidities associated with uncontrolled gout.

Important trial on the podcast this week! I take a deep dive into the recently published SAPHYR study, which evaluated the use of the IL6 inhibitor sarilumab for patients with PMR. A few aggravating quibbles but overall a very useful trial and an important step forward for patients with PMR. Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2303…

This week I took a twitter disagreement from the impersonal world of twitter to the podcast world of a back and forth conversation. Really enjoyed talking to Dr. Len Calabrese about monoclonal antibodies, FDA regulatory pathways, and life in general.By Michael Putman

Excited to share an editorial that I wrote along with Cody Bruggemeyer and Desh Nepal, two trainees with me at the Medical College of Wisconsin. We discussed what I believe to be a pervasive (but seldom discussed) issue in rheumatology RCTs: unblinding. I suspect many of our studies suffer from this. Have a listen!…

Happy to share the FIRST randomized trial in CPPD today. It's kind of a weird study but worth a quick discussion. https://www.sciencedirect.com/science/article/pii/S2665991323001650By Michael Putman

This week I dive into the health related quality of life measures that were reported in the ADVOCATE study. I found them overall somewhat convincing and they have affected my practice. Have a listen and be sure to follow along. Find my work at ebrheum.comBy Michael Putman

Quick episode this week from a recent Perspective piece I had published in the New England Journal. Have a listen or a read! https://www.nejm.org/doi/full/10.1056/NEJMp2304828By Michael Putman

In this podcast, expert clinicians will discuss the current tools available for outpatient management of COVID-19 and provide updates on emerging options for preexposure prophylaxis.

Podcast this week discussing key opinion leaders (KOLs) and pharmaceutical companies. Please subscribe to my newsletter (ebrheum.com) and be sure to share the podcast with friends!By Michael Putman

In this podcast, expert clinicians will discuss current unmet needs regarding patient education and review strategic messaging to enhance the preparedness of immunocompromised patients at risk for COVID-19.

In this podcast, expert clinicians will discuss outpatient management of COVID-19 and strategies to educate practitioners on best practices for those caring for immunocompromised patients.

In this podcast, expert clinicians will discuss how immune compromising conditions and iatrogenic causes of immune suppression affect risk for infection and severe outcomes with COVID-19.

In this podcast, expert clinicians will review clinical cases of varying severity to highlight evidence-based approaches for management of EGPA.

In this podcast, expert clinicians will discuss evidence-based practices on the appropriate use of glucocorticoids, immunosuppressants, and targeted therapy for induction and maintenance of remission in severe and non-severe forms of EGPA.

In this podcast, expert clinicians will examine diagnostic approaches that can be used to distinguish EGPA from other vasculitides and hypereosinophilic conditions.

In this podcast, expert clinicians will review the underlying immunopathology and various clinical presentations of EGPA and discuss its impact on patient quality of life.

Nice quick RCT rundown this week, covering the ALLHEART study, a pragmatic RCT of urate lowering therapy to reduce cardiovascular disease. Quick listen for a useful teaching point! https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01657-9/fulltextBy Michael Putman

In this podcast, expert clinicians will review recent developments involving monoclonal antibody therapies for COVID-19 and discuss ongoing studies on pre-exposure prophylaxis for immunocompromised patients.

Today I cover the recently published long-COVID study from Norway. It's a great paper that challenges much of the prevailing wisdom. I think there are some interesting limitations, but anyone who sees post COVID patients (aka all of us) would do well to read it. Or have a listen here! PDF: https://jamanetwork.com/journals/jamanetworkopen/fullarticl…

Fun study this week from JAMA Network Open and the French Vasculitis Study Group. They used a target trial emulation (one of my favorites) to ask whether RTX > CYC in AAV (another one of my favorites). I tried to use this to compare between observational and randomized data. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799018…

In this podcast, expert clinicians will review a challenging case of systemic lupus erythematosus and discuss new or emerging therapeutic options that may be of benefit.

In this podcast, expert clinicians will review a challenging case of vasculitis and discuss new or emerging therapeutic options that may be of benefit.

In this podcast, expert clinicians will review a challenging case of psoriatic arthritis and discuss new or emerging therapeutic options that may be of benefit.

In In this podcast, expert clinicians will discuss recent developments involving COVID-19 PrEP as well as current challenges and opportunities.

This week I hope to debunk one of rheumatology's "paradoxes." We love to talk about these and subject our fellows to memorizing them for the boards. We often use them to guide clinical practice, but I suspect that many "paradoxes" are actually the result of shoddy epidemiology. Todays' paper from JAMA dermatology covers one that I have heard freque…

Today I'll be reading one of my recent newsletters! It's kind of a fun run-down of my anti-azathioprine stance. As I say in the piece, some patients may benefit from azathioprine and I am not saying it is an entirely useless drug or that nobody should ever prescribe it. Rather, I am just saying that it is likely the worst option for nearly every in…

Today I review a recent large meta analysis of randomized controlled trials of statin use. Super interesting findings that have changed my clinical practice. Check out the paper here and listen to the episode! Paper: https://www.thelancet.com/article/S0140-6736(22)01545-8/fulltext "Internet driven cult" editorial: https://pubmed.ncbi.nlm.nih.gov/28…

Change of pace today! I interviewed Jason Liebowitz and Phil Seo about their new book entitled "Clinical Innovation in Rheumatology: Past, Present, and Future." I thoroughly enjoyed the book and had a great time interviewing them about some of their "futuristic" topics. Grab the book (or better yet, have your division get some copies) at the link b…

Quick episode this week to share an editorial I recently wrote with Jay Patel and Anisha Dua. We cover one of my least phrases in medicine, the "diagnosis of exclusion." Hope you enjoy! Find the original paper here: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keac278/6584804…

Exciting (negative) results from a large RCT on the podcast this week as well as a (mini) rant about how we should be spending our time as rheumatologists and the false security of ineffective treatments. Let me know what you think on twitter @ebhruem https://www.nejm.org/doi/full/10.1056/NEJMoa2202106…

Interesting case-crossover study today evaluating the association between HCQ dosing and risk of SLE flares. Super worth your time to read the paper or listen to this episode! https://jamanetwork.com/journals/jama/article-abstract/2796634By Michael Putman

In this podcast, expert clinicians will discuss the promise of identifying and targeting the dominant cytokine networks active in the various disorders of IMID.

In this podcast, expert clinicians will review recent updates in the safety data regarding Janus kinase (JAK) inhibitors and discuss the appropriate selection of candidates for safe and effective use of JAK inhibitor therapy.

In this podcast, expert clinicians will discuss the safety and efficacy of interleukin-17/23 inhibitors for the management of inflammatory skin and joint diseases.

Podcast is back! This week I discuss a pivotal RCT in dermatomyositis. Check it out and be sure to subscribe to my newsletter at ebrheum.com!By Michael Putman

Mixing it up again this week to discuss an editorial by Miguel Hernan and a systematic review of target trials in rheumatology. It's kind of a fun free-form stream of consciousness. Hope you enjoy! Links: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888052/ https://pubmed.ncbi.nlm.nih.gov/32381560/By Michael Putman

Quick episode today. I wanted to share an editorial that was recently published in Rheumatology, where I and co-authors (Shannon Tai and Natalie Anumolu) discuss lessons from recent trials in AAV and SLE. Link to editorial: https://pubmed.ncbi.nlm.nih.gov/35438142/By Michael Putman

After some delay, I finally get around to discussing ORAL-Surveillance, a post-marketing safety study of tofacitinib for rheumatoid arthritis. It's an incredibly important trial that will likely affect how all of us practice for the foreseeable future. Link to paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2109927…

After a winter hiatus, the podcast is back! Today I wanted to dive into a 'hotbutton' issue - the question of whether (or not) COVID-19 vaccines "work" for patients with rheumatic diseases. My answer is an emphatic "yes," albeit with a few caveats. Here are the papers I discuss: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)000…

In this Curbside Consults video, Drs. Calabrese and Cron discuss the case of a young adult with COVID-19 who experiences serious complications due to hyperinflammation.

In this Curbside Consults video, Drs. Calabrese and Tien discuss the workup and management of a 79-year-old man who is admitted to the hospital with rapidly worsening COVID-19 pneumonia.